<DOC>
	<DOC>NCT00380874</DOC>
	<brief_summary>Prevention and treatment of the severity of symptoms of chemotherapy-induced peripheral neuropathy.</brief_summary>
	<brief_title>Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer</brief_title>
	<detailed_description>This study was terminated on July 15, 2008. The results of an interim analysis showed that the conditional power to detect a difference in treatment groups was insufficient to warrant study continuation and therefore termination of the trial was recommended. The decision to terminate the trial was not based on safety concerns.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Diagnosis of cytological confirmed carcinoma of the Colon Stage III (Dukes C) or metastatic Colorectal Cancer (Dukes D) Independent of this protocol, the patient has decided to receive standard of care for the treatment of cancer with oxaliplatin combined with 5fluorouracil/folinic acid (5FU/FA) for a minimum of 9 cycles Presence of neuropathic pain or peripheral polyneuropathy or identified causes of painful paresthesia including radiotherapyinduced or malignant plexopathy, lumbar or cervical radiculopathy existing prior to baseline Any patients who are not suitable to be treated with either Oxaliplatin and/or 5FU/FA or pregabalin according to the respective local labeling</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Pain</keyword>
	<keyword>chemotherapy</keyword>
</DOC>